Mendeley  

Zotero  

Mohammadi S, Ebadpor M, Sedighi S, Memarian A. Title: Association of glucocorticoids treatment and IL-17 production among systemic lupus erythematosus patients. Zanko J Med Sci 2019; 20 (66) :1-10
URL: http://zanko.muk.ac.ir/article-1-467-en.html

Background and Aim: Systemic lupus erythematosus (SLE) is an autoimmune disease with chronic inflammatory immune response. Current therapies mostly rely on glucocorticoids which are accompanied by side-effects and mostly fail to achieve a favorable remission. Th17 subpopulation of T cells are increased in exacerbated SLE. IL-17 cytokine is also overexpressed. Although IL-17 is reported to be resistant to glucocorticoids in various disorders, we evaluated the plasma level of IL-17 in newly diagnosed and under-treatment SLE patients to understand the effect of glucocorticoids on Th17 response.
Material and Method: A total of 40 female SLE patients and 20 age- and sex- matched normal subjects were enrolled. IL-17 plasma level was measured using ELISA assay and analyzed with previously obtained IL-10, IFN-γ, and GILZ levels.
Results: It was revealed that IL-17 was overexpressed in under-treatment SLE patients. There was a significant correlation between IL-17 and IFN-γ. Significant reverse correlations were found between IL-17, IL-10, and GILZ levels. IL-17 was not significantly correlated with the disease activity.
Conclusion: According to the role of IL-17 in tissue injury and the fact that glucocorticoids are not successful in preventing organ damages in SLE, the overexpressed IL-17 despite therapies, could be introduced as an underlying reason.